Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

T.P. Hughes; A Hochhaus; H.M. Kantarjian; F. Cervantes; F. Guilhot; D. Niederwieser; P.D. le Coutre; G. Rosti; G.J. Ossenkoppele; C. Lobo; H. Shibayama; X.L. Fan; H.D. Menssen; C. Kemp; R.A. Larson; G. Saglio

doi:10.3324/haematol.2013.091272

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

T.P. Hughes, A Hochhaus, H.M. Kantarjian, F. Cervantes, F. Guilhot, D. Niederwieser, P.D. le Coutre, G. Rosti, G.J. Ossenkoppele, C. Lobo, H. Shibayama, X.L. Fan, H.D. Menssen, C. Kemp, R.A. Larson, G. Saglio

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	1204-1211
Journal	Haematologica
Volume	99
Issue number	7
DOIs	https://doi.org/10.3324/haematol.2013.091272
Publication status	Published - 2014

Access to Document

10.3324/haematol.2013.091272

Cite this

Hughes, T. P., Hochhaus, A., Kantarjian, H. M., Cervantes, F., Guilhot, F., Niederwieser, D., ... Saglio, G. (2014). Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica, 99(7), 1204-1211. https://doi.org/10.3324/haematol.2013.091272

Hughes, T.P. ; Hochhaus, A ; Kantarjian, H.M. ; Cervantes, F. ; Guilhot, F. ; Niederwieser, D. ; le Coutre, P.D. ; Rosti, G. ; Ossenkoppele, G.J. ; Lobo, C. ; Shibayama, H. ; Fan, X.L. ; Menssen, H.D. ; Kemp, C. ; Larson, R.A. ; Saglio, G. / Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. In: Haematologica. 2014 ; Vol. 99, No. 7. pp. 1204-1211.

@article{707ea2d8d71f465d99224bd40eeab55f,

title = "Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily",

author = "T.P. Hughes and A Hochhaus and H.M. Kantarjian and F. Cervantes and F. Guilhot and D. Niederwieser and {le Coutre}, P.D. and G. Rosti and G.J. Ossenkoppele and C. Lobo and H. Shibayama and X.L. Fan and H.D. Menssen and C. Kemp and R.A. Larson and G. Saglio",

year = "2014",

doi = "10.3324/haematol.2013.091272",

language = "Undefined/Unknown",

volume = "99",

pages = "1204--1211",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "7",

}

Hughes, TP, Hochhaus, A, Kantarjian, HM, Cervantes, F, Guilhot, F, Niederwieser, D, le Coutre, PD, Rosti, G, Ossenkoppele, GJ, Lobo, C, Shibayama, H, Fan, XL, Menssen, HD, Kemp, C, Larson, RA & Saglio, G 2014, 'Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily', Haematologica, vol. 99, no. 7, pp. 1204-1211. https://doi.org/10.3324/haematol.2013.091272

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. / Hughes, T.P.; Hochhaus, A; Kantarjian, H.M.; Cervantes, F.; Guilhot, F.; Niederwieser, D.; le Coutre, P.D.; Rosti, G.; Ossenkoppele, G.J.; Lobo, C.; Shibayama, H.; Fan, X.L.; Menssen, H.D.; Kemp, C.; Larson, R.A.; Saglio, G.

In: Haematologica, Vol. 99, No. 7, 2014, p. 1204-1211.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

AU - Hughes, T.P.

AU - Hochhaus, A

AU - Kantarjian, H.M.

AU - Cervantes, F.

AU - Guilhot, F.

AU - Niederwieser, D.

AU - le Coutre, P.D.

AU - Rosti, G.

AU - Ossenkoppele, G.J.

AU - Lobo, C.

AU - Shibayama, H.

AU - Fan, X.L.

AU - Menssen, H.D.

AU - Kemp, C.

AU - Larson, R.A.

AU - Saglio, G.

PY - 2014

Y1 - 2014

U2 - 10.3324/haematol.2013.091272

DO - 10.3324/haematol.2013.091272

M3 - Article

C2 - 24532039

VL - 99

SP - 1204

EP - 1211

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 7

ER -

Hughes TP, Hochhaus A, Kantarjian HM, Cervantes F, Guilhot F, Niederwieser D et al. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica. 2014;99(7):1204-1211. https://doi.org/10.3324/haematol.2013.091272